New shot aims to fortify fragile bones in brittle bone disease trial
Disease control
Recruiting now
This study tests a drug called AGA2115 in 80 adults with osteogenesis imperfecta (brittle bone disease) types I, III, or IV. Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug increases bone density in the spine after 1…
Phase: PHASE2 • Sponsor: Angitia Incorporated Limited • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC